Also found in: Dictionary, Wikipedia.

insulin aspart (rDNA origin)


insulin aspart and insulin aspart protamine

NovoLog Mix 70/30

Pharmacologic class: Pancreatic hormone

Therapeutic class: Hypoglycemic

Pregnancy risk category C


Short-acting insulin form. Promotes glucose transport, which stimulates carbohydrate metabolism in skeletal and cardiac muscle and adipose tissue. Also promotes phosphorylation of glucose in liver, where it's converted to glycogen. Directly affects fat and protein metabolism, stimulates protein synthesis, inhibits release of free fatty acids, and indirectly decreases phosphate and potassium.


Injection (NovoLog): 100 units/ml in 10-ml vials and 3-ml PenFill cartridges

Injection (NovoLog Mix 70/30): 100 units/ml in 10-ml vials, 3-ml PenFill cartridges, and 3-ml FlexPen prefilled syringes

Indications and dosages

Type 1 (insulin-dependent) diabetes mellitus; type 2 (non-insulin-dependent) diabetes mellitus

Adults and children ages 6 and older: Insulin aspart-Dosage tailored to patient's needs, given subcutaneously in divided doses 5 to 10 minutes before meals. Insulin aspart provides 50% to 70% of dose; intermediate or long-acting insulin provides remainder. Dosage range is 0.5 to 1 unit/kg/day in divided doses based on meals. Insulin aspart and insulin aspart protamine- Give subcutaneously b.i.d., 15 minutes before morning and evening meals. For monotherapy, initial dosage is 0.4 to 0.6 unit/kg/day in two divided doses. Titrate in increments of 2 to 4 units q 3 to 4 days to achieve target fasting plasma glucose level. When given with oral hypoglycemics, initial dosage is 0.2 to 0.3 unit/kg/day.


• Hypersensitivity to drug or its components

• Hypoglycemia


Use cautiously in:

• hepatic or renal impairment, hypothyroidism, hyperthyroidism

• elderly patients

• pregnant or breastfeeding patients

• children.


Be aware that insulin is a high-alert drug.

• Know that drug is bioavailable as regular human insulin but has a faster onset and shorter duration.

• Give by subcutaneous route only, 5 to 10 minutes (15 minutes for Novolog Mix 70/30) before a meal.

• When mixing insulin aspart with intermediate or long-acting insulin, draw up insulin aspart into syringe first.

Don't mix insulin aspart protamine with any other insulin.

• When giving insulin aspart by pump, don't mix with other insulins.

• Rotate injection sites to prevent lipodystrophy.

Adverse reactions

Metabolic: hypokalemia, sodium retention, hypoglycemia, rebound hyperglycemia (Somogyi effect)

Musculoskeletal: myalgia

Skin: urticaria, rash, pruritus

Other: edema; lipodystrophy; lipohypertrophy; redness, warmth, or stinging at injection site; allergic reactions including anaphylaxis


Drug-drug. Acetazolamide, albuterol, antiretrovirals, asparaginase, calcitonin, corticosteroids, cyclophosphamide, danazol, dextrothyroxine, diazoxide, diltiazem, diuretics, dobutamine, epinephrine, estrogens, hormonal contraceptives, isoniazid, morphine, niacin, phenothiazines, phenytoin, somatropin, terbutaline, thyroid hormones: decreased hypoglycemic effect

Anabolic steroids, angiotensin-converting enzyme inhibitors, calcium, chloroquine, clofibrate, clonidine, disopyramide, fluoxetine, guanethidine, mebendazole, MAO inhibitors, octreotide, oral hypoglycemics, phenylbutazone, propoxyphene, pyridoxine, salicylates, sulfinpyrazone, sulfonamides, tetracyclines: increased hypoglycemic effect

Beta-adrenergic blockers (nonselective): masking of some hypoglycemia signs and symptoms, delayed recovery from hypoglycemia

Lithium carbonate: decreased or increased hypoglycemic effect

Pentamidine: increased hypoglycemic effect, possibly followed by hyperglycemia

Drug-diagnostic tests. Glucose, inorganic phosphate, magnesium, potassium: decreased levels

Liver and thyroid function studies: test interference

Urine vanillylmandelic acid: increased level

Drug-herbs. Basil, bee pollen, burdock, glucosamine, sage: altered glycemic control

Chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek, marshmallow: increased hypoglycemic effect

Garlic, ginseng: decreased blood glucose level

Drug-behaviors. Alcohol use: increased hypoglycemic effect

Marijuana use: increased blood glucose level

Smoking: increased blood glucose level, decreased response to insulin

Patient monitoring

• Monitor blood glucose level frequently to gauge drug efficacy and appropriateness of dosage.

• Watch blood glucose level closely if patient is converting from one insulin type to another or is under unusual stress (as from surgery or trauma).

Stay alert for signs and symptoms of hypoglycemia. Keep glucose source at hand.

Assess for evidence of hyperglycemia, such as polydipsia, polyphagia, polyuria, and diabetic ketoacidosis (as shown by urine and blood ketones, metabolic acidosis, extremely elevated blood glucose level, and hypovolemia).

• Monitor for glycosuria.

• Closely monitor kidney and liver function test results in patients with renal or hepatic impairment.

Patient teaching

• Teach patient how to administer insulin subcutaneously or by injection pen.

• If patient must mix insulin aspart with intermediate or long-acting insulin, instruct him to draw up insulin aspart into syringe first.

Tell patient not to mix any other insulin with mixture of insulin aspart and insulin aspart protamine.

• Advise patient to rotate subcutaneous injection sites and keep a record of sites used, to help prevent fatty tissue breakdown.

Teach patient how to recognize and report signs and symptoms of hypoglycemia and hyperglycemia. Advise him to always carry a glucose source.

• Inform patient that changes in diet, activity, and stress level affect blood glucose levels and insulin requirements.

• Teach patient how to monitor and record blood glucose level and, if indicated, urine glucose and ketone levels.

• Tell patient to wear medical identification stating that he is diabetic and takes insulin.

• Instruct patient to have regular medical, vision, and dental exams.

• Tell female patient to contact prescriber if she is pregnant or plans to become pregnant.

• Advise patient to store insulin in refrigerator, not freezer.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

insulin aspart

(in-su-lin as-spart) ,


(trade name),


(trade name)

insulin aspart protamine suspension/insulin aspart injection mixture


NovoLOG Mix 70/30

(trade name),

Novomix 30

(trade name)


Therapeutic: antidiabetics
Pharmacologic: pancreatics
Pregnancy Category: B (insulin aspart)
Pregnancy Category: C (insulin aspart protamine suspension/insulin aspart injection mixtures)


Control of hyperglycemia in patients with type 1 or type 2 diabetes mellitus.


Lowers blood glucose by :
  • stimulating glucose uptake in skeletal muscle and fat,
  • inhibiting hepatic glucose production.
Other actions of insulin:
  • inhibition of lipolysis and proteolysis,
  • enhanced protein synthesis.
A rapid-acting insulin with more rapid onset and shorter duration than human regular insulin; should be used with an intermediate- or long-acting insulin.

Therapeutic effects

Control of hyperglycemia in diabetic patients.


Absorption: Rapid acting.
Distribution: Identical to endogenous insulin.
Metabolism and Excretion: Metabolized by liver, spleen, kidney, and muscle.
Half-life: Approximately 60–90 min.

Time/action profile (hypoglycemic effect)

Subcutwithin 15 min1–2 hr3–4 hr


Contraindicated in: Hypoglycemia; Allergy or hypersensitivity to insulin aspart.
Use Cautiously in: Stress and infection, which may temporarily ↑ insulin requirements; Renal/hepatic impairment (may ↓ insulin requirements); Must be used with a longer-acting insulin in patients with type 1 diabetes; Concomitant use with pioglitazone or rosiglitazone (↑ risk of fluid retention and worsening HF) Obstetric: May temporarily ↑ insulin requirements; Pediatric: Children <6 yr (safety not established).

Adverse Reactions/Side Effects


  • hypoglycemia (life-threatening)


  • lipodystrophy
  • pruritis
  • erythema
  • swelling


  • allergic reactions including anaphylaxis (life-threatening)


Drug-Drug interaction

Beta blockers and clonidine may mask some of the signs and symptoms of hypoglycemia.Corticosteroids, thyroid supplements, estrogens, isoniazid, niacin,phenothiazines, and rifampin may ↑ insulin requirements.Alcohol, ACE inhibitors, MAO inhibitors, octreotide, oral hypoglycemic agents, and salicylates, may ↓ insulin requirements.Concurrent use with pioglitazone or rosiglitazone may ↑ risk of fluid retention and worsening HFGlucosamine may worsen blood glucose control.Fenugreek, chromium, and coenzyme Q-10 may produce additive hypoglycemic effects.


Subcutaneous (Adults and Children) Determined by needs of the patients; generally 0.5–1 units/kg/day total. 50–70% may be given as insulin aspart, and the remainder as intermediate- or long-acting insulin. May also be given via subcutaneous infusion pump; initial programming based on total daily dose of insulin given in previous regimen with 50% of total daily dose given as premeal boluses and 50% of total daily dose given as basal infusion; dose can then be adjusted based on response.


Insulin aspart: 100 units/mL in 10-mL vials and 3-mL PenFill cartidges for use with NovoPen 4 Insulin Delivery Devices and NovoFine disposable needles
Insulin aspart protamine suspension/insulin aspart injection mixture: 70% insulin aspart protamine suspension and 30% insulin aspart injection—NovoLog Mix 70/30 100 units/mL in 10-mL vials and 3-mL disposable delivery devices

Nursing implications

Nursing assessment

  • Assess for symptoms of hypoglycemia (anxiety; restlessness; tingling in hands, feet, lips, or tongue; chills; cold sweats; confusion; cool, pale skin; difficulty in concentration; drowsiness; nightmares or trouble sleeping; excessive hunger; headache; irritability; nausea; nervousness; tachycardia; tremor; weakness; unsteady gait)and hyperglycemia (confusion, drowsiness; flushed, dry skin; fruit-like breath odor; rapid, deep breathing, polyuria; loss of appetite; nausea; vomiting; unusual thirst) during therapy.
  • Monitor body weight periodically. Changes in weight may necessitate changes in insulin dose.
  • Lab Test Considerations: Monitor blood glucose every 6 hr during therapy, more frequently in ketoacidosis and times of stress. A1C may be monitored every 3–6 mo to determine effectiveness.
  • Overdose is manifested by symptoms of hypoglycemia. Mild hypoglycemia may be treated by ingestion of oral glucose. Severe hypoglycemia is a life-threatening emergency; treatment consists of IV glucose, glucagon, or epinephrine.

Potential Nursing Diagnoses

Noncompliance (Patient/Family Teaching)


  • high alert: Medication errors involving insulins have resulted in serious patient harm and death. Clarify all ambiguous orders and do not accept orders using the abbreviation “u” for units, which can be misread as a zero or the numeral 4 and has resulted in tenfold overdoses. Insulins are available in different types and strengths. Check type, dose, and expiration date with another licensed nurse. Do not interchange insulins without consulting physician or other health care professional.
  • Do not confuse Novolog with Novolin.
  • Due to the short duration of action, insulin aspart must be used with a longer-acting insulin or insulin infusion pump therapy.
  • Check type, species source, dose, and expiration date with another licensed nurse. Do not interchange insulins without consulting physician or other health care professional.
    • Use only insulin syringes to draw up dose. The unit markings on the insulin syringe must match the insulin's units/mL.
    • When mixing insulins, draw insulin aspart into syringe first to avoid contamination of regular insulin vial. Administer immediately after mixing. Do not mix with crystalline zinc insulin preparations.
    • Insulin aspart should be refrigerated, but do not freeze or administer solution if it has been frozen. Cartridges or vials may be kept at room temperature for up to 28 days if kept from excessive heat and sunlight. Do not use if cloudy, discolored, or unusually viscous. Never use the PenFill cartridge after the expiration date on the PenFill cartridge or on the box.
    • Because of the short duration of insulin aspart, supplementation with longer-acting insulin is usually necessary to control blood glucose levels.
  • Subcutaneous: Administer insulin aspart subcut in the abdominal wall, thigh, or upper arm within 5–10 min before a meal. Rotate injection sites.
    • When used in pumps: Change the solution in the reservoir at least every 6 days, change the infusion set, and the infusion set insertion site at least every 3 days. Do not mix with other insulins or with a diluent when used in the pump.
  • Intravenous Administration
  • pH: 7.2–7.6.
  • Intravenous: May be given IV in selected clinical situations under appropriate medical supervision. Diluent: Dilute with 0.9% NaCl or D5W in infusion systems using polypropylene infusion bags. Concentration: 0.05–1 unit/mL.
  • May be administered via disposable external insulin pump. Do not administer solution that appears thickened, cloudy, discolored, or contains particles. Store cartridges for pump in refrigerator. Do not mix with other insulins or solutions when used with pump. Choose a new infusion site every 48 hr. Discard cartridges after 7 days, even if solution remains.

Patient/Family Teaching

  • Instruct patient on proper technique for administration. Include type of insulin, equipment (syringe, cartridge pens, external pumps, alcohol swabs), storage, and place to discard syringes. Discuss the importance of not changing brands of insulin or syringes, selection and rotation of injection sites, and compliance with therapeutic regimen. Caution patient that insulin pens should not be shared with others, even if clean needles are used.
  • Demonstrate technique for mixing insulins by drawing up insulin aspart first and rolling intermediate-acting insulin vial between palms to mix, rather than shaking (may cause inaccurate dose).
  • Explain to patient that this medication controls hyperglycemia but does not cure diabetes. Therapy is long term.
  • Instruct patient in proper testing of serum glucose and ketones. These tests should be closely monitored during periods of stress or illness and health care professional notified of significant changes.
  • Emphasize the importance of compliance with nutritional guidelines and regular exercise as directed by health care professional.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
  • Advise patient to notify health care professional if nausea, vomiting, or fever develops, if unable to eat regular diet, or if blood sugar levels are not controlled.
  • Instruct patient on signs and symptoms of hypoglycemia and hyperglycemia and what to do if they occur.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding or planning to breastfeed.
  • Patients with diabetes mellitus should carry a source of sugar (candy, glucose gel) and identification describing their disease and treatment regimen at all times.
  • Emphasize the importance of regular follow-up, especially during first few weeks of therapy.

Evaluation/Desired Outcomes

  • Control of blood glucose levels in diabetic patients without hypoglycemic or hyperglycemic episodes.
Drug Guide, © 2015 Farlex and Partners


(nō′vō-lôg′, -lŏg′, -və-)
A trademark for the drug insulin aspart.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.
References in periodicals archive ?
Lantus was increased to 40 units every morning and NovoLog was increased 13 units 3 times a day with meals.
In conjunction, Fiasp will launch at the same list price as NovoLog and will be offered with a Savings Card programme for eligible patients with commercial insurance to reduce co-pays.
In 2012, the worldwide net sales of Lantus, Humalog and NovoLog were about USD11.5bn, according to public filings.
The analogues lispro (Humalog) and aspart (Novolog) may be advantageous, for instance, for the pregnant woman "with a toddler around who may not know when she is going to sit down to eat," Dr.
However, beginning in April 2007, the hospital staff members have changed their sliding scale formulary from regular human insulin to Aspart injection insulin (NovoLog), which has a much different pharmacology profile.
In addition, the nasal spray performed as well as NovoLog, a rapid-acting injectable insulin.
SmartCenter Noble Systems Noble Composer Corporation Web Agent Novo NovoLog Suite Technologies inc.
Kaufman said Apidra is comparable to the two other approved rapid-acting insulins, insulin lispro and insulin aspart (NovoLog, Novo Nordisk).
The physician writes "Novolog 10 units now and 10 units Novolin at bedtime." The staff member reads the order and proceeds to administer the Novolog 10 units.
Novo Nordisk's FlexPen is the leading insulin delivery device in the United States and is used with Novo Nordisk's NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, (rDNA origin)), NovoLog (insulin aspart (rDNA origin) injection) and soon-to-be-launched Levemir (insulin detemir (rDNA origin) injection).
The Global Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.